Last $77.59 USD
Change Today -1.22 / -1.55%
Volume 8.8M
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic plc (MDT) Snapshot

Open
$78.53
Previous Close
$78.81
Day High
$78.76
Day Low
$77.56
52 Week High
02/23/15 - $79.45
52 Week Low
04/14/14 - $55.85
Market Cap
110.6B
Average Volume 10 Days
7.4M
EPS TTM
$4.02
Shares Outstanding
1.4B
EX-Date
03/26/15
P/E TM
19.3x
Dividend
$1.22
Dividend Yield
1.54%
Current Stock Chart for MEDTRONIC PLC (MDT)

medtronic plc (MDT) Details

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company also offers a portfolio of surgical, respiratory and monitoring, and vascular therapies solutions, as well as medical supplies. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

49,247 Employees
Last Reported Date: 09/19/14
Founded in 1949

medtronic plc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic plc (MDT) Key Developments

Irish High Court Approves Medtronic Plc's Quarterly Dividend, Payable on April 17, 2015

Medtronic plc announced that the Irish High Court has approved the company's share premium reduction petition, creating the distributable reserves needed to support share repurchases or redemptions and payment of the cash dividend of $0.305 per ordinary share that was previously announced on February 13, 2015. The dividend remains payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year.

Medtronic Files Form 15

Medtronic, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock, par value $0.10 per share under the Securities Exchange Act of 1934, as amended.

FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux

Medtronic plc announced U.S. Food and Drug Administration approval for VenaSeal (TM) closure system, a minimally invasive procedure that uses a specially formulated medical adhesive to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux. Venous reflux disease, also known as chronic venous insufficiency, occurs when valves in the veins of the lower leg no longer function properly. This allows blood to flow backward, or reflux, resulting in enlarged, or varicose veins as well as other symptoms. If left untreated, the condition can progress and, in severe cases, can result in lifestyle-limiting lower leg pain, swelling, skin damage and ulcerations. The VenaSeal procedure is the only non-tumescent, non-thermal, non-sclerosant procedure approved for use in the U.S. that uses a specially formulated medical adhesive that closes the vein. This unique approach may eliminate the risk of nerve injury that is sometimes associated with certain thermal-based procedures. The procedure is administered without the use of tumescent anesthesia, minimizing the need for multiple needle sticks. Patients also report minimal-to-no bruising post procedure.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $77.59 USD -1.22

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $168.65 USD -0.96
Allergan Inc/United States $232.74 USD +0.34
Astellas Pharma Inc ¥1,901 JPY +3.00
Koninklijke Philips NV €26.77 EUR +0.175
Stryker Corp $94.75 USD +0.35
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 24.9x
Price/Sales 4.4x
Price/Book 3.8x
Price/Cash Flow 31.7x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.